FDA Approves First New Bladder Cancer Therapy in 30 Years Using Immune Checkpoint Combo

Bladder cancer treatment has been largely unchanged for decades, making this FDA approval a landmark moment in oncology. For patients diagnosed with high-risk non-muscle-invasive bladder cancer (NMIBC), the risk of recurrence is significant, often leading to repeated surgeries and, in serious cases, complete surgical removal of the bladder — a life-altering outcome that this new regimen aims to prevent.

The FDA's approval of durvalumab (Imfinzi) in combination with BCG therapy is grounded in results from the phase III POTOMAC trial, a robust randomized study enrolling 1,018 patients. Those receiving the combination therapy showed a hazard ratio of 0.68 for disease-free survival, meaning roughly a 32% reduction in the risk of recurrence, progression, or death compared to BCG alone. Median disease-free survival had not yet been reached in either arm — a positive indicator suggesting durable benefit.

Durvalumab is an immune checkpoint inhibitor that blocks the PD-L1 protein, releasing the immune system's brakes and allowing it to more aggressively attack cancer cells. Pairing it with BCG, which has been the standard immunotherapy for bladder cancer since the 1970s, appears to create a synergistic immune response that the body sustains over time.

New data presented at the 2026 American Urological Association meeting reinforced these findings, showing the combination also reduced early high-risk recurrences within the first 12 months — often the most critical window for disease control.

However, the therapy carries important safety warnings, including immune-mediated adverse reactions and risks for specific patient subgroups. This approval applies specifically to BCG-naive patients — those who have not previously received BCG — so its applicability is defined. Patients and clinicians should discuss individual risk-benefit profiles, and longer-term survival data are still awaited.